Objective To observe the pegylated interferon (Peg-IFN) α-2a combined with ribavirin ribavirin for hepatitis C with cirrhosis spleen function hyperthyroidism patients splenectomy or partial splenic embolization efficacy of antiviral therapy. Methods After the merger of the 31 patients with hepatitis C cirrhosis (genotype Ⅰ HCV infection) hypersplenism fails to make the anti-viral therapy, to improve the line splenectomy or partial splenic embolization for hypersplenism 2 months, to give Peg-IFNα-2a 135μg or 180μg subcutaneously, once weekly plus ribavirin 800-1200mg/d for 48 weeks of the treatment. During the treatment the 1, 2, 4, 6, 8, 12-week follow-up after follow-up every 4 weeks, continue to observe the 24 weeks after stopping. Adverse liver function, blood count, renal function, HCV RNA, and medication during treatment and during follow-up observation. Results In patients with hepatitis C with cirrhosis hypersplenism splenectomy or partial splenic embolization for the treatment of splenic function after remission given Peg-IFNα-2a combined with ribavirin anti-viral treatment of sustained virologic response rate was 64.51%. Conclusions Hepatitis C with cirrhosis spleen function in patients with hyperthyroidism, splenectomy or partial splenic embolization given Peg-IFNα-2a combined with ribavirin treatment the better the SVR, delayed the progress of the hepatitis C cirrhosisreduce the incidence of liver failure and liver cancer.% 目的观察聚乙二醇干扰素（Peg-IFN)α-2a 联合利巴韦林对丙型肝炎肝硬化合并脾功能亢进患者在脾切除或部分脾栓塞术后抗病毒治疗的疗效。方法将31例丙型肝炎肝硬化（基因Ⅰ型 HCV 感染）合并脾功能亢进而未作抗病毒治疗的患者，在行脾切除术或部分脾栓塞术，脾功能亢进改善2个月后，给予 Peg-IFNα-2a 135μg 或180μg 皮下注射，每周1次，联合利巴韦林800~1200mg/d 治疗，疗程48周。治疗期间，第1、2、4、6、8、12周随访，之后每4周随访1次，停药后继续观察24周。治疗及随访期间观察肝功能、血常规、肾功能、HCV RNA 及用药期间的不良反应。结果丙型肝炎肝硬化合并脾功能亢进患者采用脾切除或部分脾栓塞术治疗脾功能缓解后，给予 Peg-IFNα-2a 联合利巴韦林抗病毒治疗其持续病毒学应答率为64.51%。结论丙型肝炎肝硬化合并脾功能亢进的患者，在脾切除或部分脾栓塞术后给予 Peg-IFNα-2a 联合利巴韦林治疗有较好的 SVR，延缓了丙型肝炎肝硬化的进展，减少了肝衰竭及肝癌的发生。
展开▼
